Your browser doesn't support javascript.
Real-world clinical outcomes of treatment with casirivimab-imdevimab among patients with mild-to-moderate coronavirus disease 2019 during the Delta variant pandemic.
Suzuki, Yasuhito; Shibata, Yoko; Minemura, Hiroyuki; Nikaido, Takefumi; Tanino, Yoshinori; Fukuhara, Atsuro; Kanno, Ryuzo; Saito, Hiroyuki; Suzuki, Shuzo; Ishii, Taeko; Inokoshi, Yayoi; Sando, Eiichiro; Sakuma, Hirofumi; Kobayashi, Tatsuho; Kume, Hiroaki; Kamimoto, Masahiro; Aoki, Hideko; Takama, Akira; Kamiyama, Takamichi; Nakayama, Masaru; Saito, Kiyoshi; Tanigawa, Koichi; Sato, Masahiko; Kanbe, Toshiyuki; Kanzaki, Norio; Azuma, Teruhisa; Sakamoto, Keiji; Nakamura, Yuichi; Ohtani, Hiroshi; Waragai, Mitsuru; Maeda, Shinsaku; Ishida, Tokiya; Sugino, Keishi; Tsukada, Yasuhiko; Yamada, Ryuki; Sato, Riko; Onuma, Takumi; Tomita, Hikaru; Saito, Mikako; Watanabe, Natsumi; Rikimaru, Mami; Kawamata, Takaya; Umeda, Takashi; Morimoto, Julia; Togawa, Ryuichi; Sato, Yuki; Saito, Junpei; Kanazawa, Kenya; Iseki, Ken.
  • Suzuki Y; Department of Pulmonary Medicine, Fukushima Medical University, Fukushima, Japan.
  • Shibata Y; Department of Pulmonary Medicine, Fukushima Medical University, Fukushima, Japan.
  • Minemura H; Department of Pulmonary Medicine, Fukushima Medical University, Fukushima, Japan.
  • Nikaido T; Department of Pulmonary Medicine, Fukushima Medical University, Fukushima, Japan.
  • Tanino Y; Department of Pulmonary Medicine, Ohara General Hospital, Fukushima, Japan.
  • Fukuhara A; Department of Pulmonary Medicine, Fukushima Medical University, Fukushima, Japan.
  • Kanno R; Department of Pulmonary Medicine, Fukushima Medical University, Fukushima, Japan.
  • Saito H; Department of Infectious Disease and Pulmonary Medicine, Aizu Medical Center, Fukushima Medical University, Fukushima, Japan.
  • Suzuki S; Department of Thoracic Surgery, Fukushima Red Cross Hospital, Fukushima, Japan.
  • Ishii T; Department of Internal Medicine, Fujita General Hospital, Fukushima, Japan.
  • Inokoshi Y; Department of Internal Medicine, Fujita General Hospital, Fukushima, Japan.
  • Sando E; Department of Pulmonary Medicine, Saiseikai Fukushima General Hospital, Fukushima, Japan.
  • Sakuma H; Department of Pulmonary Medicine, Saiseikai Fukushima General Hospital, Fukushima, Japan.
  • Kobayashi T; Department of General Internal Medicine and Clinical Infectious Diseases, Fukushima Medical University, Fukushima, Japan.
  • Kume H; Department of Internal Medicine, Saiseikai Kawamata Hospital, Fukushima, Japan.
  • Kamimoto M; Department of Emergency and Critical Care Medicine, Aizu Chuo Hospital, Fukushima, Japan.
  • Aoki H; Department of Infectious Disease and Pulmonary Medicine, Aizu Medical Center, Fukushima Medical University, Fukushima, Japan.
  • Takama A; Department of Internal Medicine, Takeda General Hospital, Fukushima, Japan.
  • Kamiyama T; Department of Pediatric Medicine, Bange Kousei General Hospital, Fukushima, Japan.
  • Nakayama M; Department of Surgery, Yurin Hospital, Fukushima, Japan.
  • Saito K; Department of Pediatric Surgery, Iwaki City Medical Center, Fukushima, Japan.
  • Tanigawa K; Department of Internal Medicine, Kashima Hospital, Fukushima, Japan.
  • Sato M; Department of Neurosurgery, Fukushima Rosai Hospital, Fukushima, Japan.
  • Kanbe T; Department of Emergency and Critical Care Medicine, Futaba Medical Center, Fukushima, Japan.
  • Kanzaki N; Department of Internal Medicine, Soma General Hospital, Fukushima, Japan.
  • Azuma T; Department of Pulmonary Medicine, Minami-Soma Municipal General Hospital, Fukushima, Japan.
  • Sakamoto K; Department of Surgery, Onahama Chuo Clinic, Fukushima, Japan.
  • Nakamura Y; Department of General Medicine, Shirakawa Satellite for Teaching and Research, Fukushima Medical University, Fukushima, Japan.
  • Ohtani H; Department of Cardiology and Vascular Medicine, Hoshi General Hospital, Fukushima, Japan.
  • Waragai M; Department of Cardiology and Vascular Medicine, Hoshi General Hospital, Fukushima, Japan.
  • Maeda S; Department of Internal Medicine, Iwase General Hospital, Sukagawa, Japan.
  • Ishida T; Department of Surgery, Southern TOHOKU General Hospital, Fukushima, Japan.
  • Sugino K; Department of Pulmonary Medicine, Jusendo General Hospital, Fukushima, Japan.
  • Tsukada Y; Department of Emergency and Critical Care Medicine, Ohta Nishinouchi Hospital, Fukushima, Japan.
  • Yamada R; Department of Respiratory Medicine, Tsuboi Hospital, Fukushima, Japan.
  • Sato R; Department of Emergency and Critical Care Medicine, Fukushima Medical University, Fukushima, Japan.
  • Onuma T; Department of Pulmonary Medicine, Fukushima Medical University, Fukushima, Japan.
  • Tomita H; Department of Pulmonary Medicine, Fukushima Medical University, Fukushima, Japan.
  • Saito M; Department of Pulmonary Medicine, Fukushima Medical University, Fukushima, Japan.
  • Watanabe N; Department of Pulmonary Medicine, Fukushima Medical University, Fukushima, Japan.
  • Rikimaru M; Department of Pulmonary Medicine, Fukushima Medical University, Fukushima, Japan.
  • Kawamata T; Department of Pulmonary Medicine, Fukushima Medical University, Fukushima, Japan.
  • Umeda T; Department of Pulmonary Medicine, Fukushima Medical University, Fukushima, Japan.
  • Morimoto J; Department of Pulmonary Medicine, Fukushima Medical University, Fukushima, Japan.
  • Togawa R; Department of Pulmonary Medicine, Fukushima Medical University, Fukushima, Japan.
  • Sato Y; Department of Pulmonary Medicine, Fukushima Medical University, Fukushima, Japan.
  • Saito J; Department of Pulmonary Medicine, Fukushima Medical University, Fukushima, Japan.
  • Kanazawa K; Department of Pulmonary Medicine, Fukushima Medical University, Fukushima, Japan.
  • Iseki K; Department of Pulmonary Medicine, Fukushima Medical University, Fukushima, Japan.
Int J Med Sci ; 19(5): 834-841, 2022.
Article in English | MEDLINE | ID: covidwho-2144950
ABSTRACT

Background:

Mutations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may reduce the efficacy of neutralizing monoclonal antibody therapy against coronavirus disease 2019 (COVID-19). We here evaluated the efficacy of casirivimab-imdevimab in patients with mild-to-moderate COVID-19 during the Delta variant surge in Fukushima Prefecture, Japan.

Methods:

We enrolled 949 patients with mild-to-moderate COVID-19 who were admitted to hospital between July 24, 2021 and September 30, 2021. Clinical deterioration after admission was compared between casirivimab-imdevimab users (n = 314) and non-users (n = 635).

Results:

The casirivimab-imdevimab users were older (P < 0.0001), had higher body temperature (≥ 38°C) (P < 0.0001) and greater rates of history of cigarette smoking (P = 0.0068), hypertension (P = 0.0004), obesity (P < 0.0001), and dyslipidemia (P < 0.0001) than the non-users. Multivariate logistic regression analysis demonstrated that receiving casirivimab-imdevimab was an independent factor for preventing deterioration (odds ratio 0.448; 95% confidence interval 0.263-0.763; P = 0.0023). Furthermore, in 222 patients who were selected from each group after matching on the propensity score, deterioration was significantly lower among those receiving casirivimab-imdevimab compared to those not receiving casirivimab-imdevimab (7.66% vs 14.0%; p = 0.021).

Conclusion:

This real-world study demonstrates that casirivimab-imdevimab contributes to the prevention of deterioration in COVID-19 patients after hospitalization during a Delta variant surge.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pandemics / COVID-19 Drug Treatment Type of study: Experimental Studies / Prognostic study Topics: Variants Limits: Humans Language: English Journal: Int J Med Sci Journal subject: Medicine Year: 2022 Document Type: Article Affiliation country: Ijms.71132

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pandemics / COVID-19 Drug Treatment Type of study: Experimental Studies / Prognostic study Topics: Variants Limits: Humans Language: English Journal: Int J Med Sci Journal subject: Medicine Year: 2022 Document Type: Article Affiliation country: Ijms.71132